UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

MEI Pharma, Inc.
(Name of Issuer)
Common Stock, \$0.00000002 par value
(Title of Class of Securities)
572322402
(CUSIP Number)
Albert Cha 575 High St. #201
Palo Alto, CA 94301
(650) 688-0818

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

with copies to:

David J. Saul, Esq. Ropes & Gray LLP 1900 University Ave, 6th Floor East Palo Alto, CA 94303

October 25, 2013

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. []

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

1.	NAME OF REPORTING PERSON.					
	Vivo Ventures VII, I	LLC				
	I.R.S. IDENTIFICA	TION NO. O	F ABOVE PERSON: 27-4484686			
2.	CHECK THE APPR	ROPRIATE B	OX IF A MEMBER OF A GROUP			
	(a) [] (b	[] (
3.	SEC USE ONLY					
4.	SOURCE OF FUNI	OS				
	00					
5.	CHECK BOX IF DI	ISCLOSURE	OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	NUMBER OF	7.	SOLE VOTING POWER	0		
	SHARES					
	BENEFICIALLY	8.	SHARED VOTING POWER	3,518,503 (1)		
	OWNED BY					
	EACH	9.	SOLE DISPOSITIVE POWER	C		
	REPORTING					
	PERSON	10.	SHARED DISPOSITIVE POWER	3,518,503 (1)		
	WITH					
11.		OUNT BENE	FICIALLY OWNED BY EACH REPORTING PERSON			
	3,518,503 (1)					
12.	CHECK BOX IF TH	HE AGGREC	GATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			
	[]					
		CC DEDDEC	ENTED BY AMOUNT IN ROW (11)	20.06% (2)		
13.	PERCENT OF CLA	SS REPRES	ENTED DI AMOGNI IN NOW (II)			
13. 14.	PERCENT OF CLA TYPE OF REPORT					

- (1) Includes 3,032,414 shares of common stock and warrants exercisable for an additional 411,041 shares held of record by Vivo Ventures Fund VII, L.P., and 66,089 shares of common stock and warrants exercisable for an additional 8,959 shares held of record by Vivo Ventures VII Affiliates Fund, L.P. Vivo Ventures VII, LLC is the sole general partner of both of the Vivo VII Funds and may be deemed to beneficially own such shares, and disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.
- (2) Based upon 17,117,152 shares of common stock outstanding as of October 24, 2013, as reported in the Issuer's prospectus supplement, dated October 25, 2013, filed pursuant to Rule 424(b)(5) on October 28, 2013.

CUSIP No. 572322402

1.	NAME OF REPOR	TING PERSC	N			
	Vivo Ventures Fund VII, L.P.					
	I.R.S. IDENTIFICA	TION NO. O	F ABOVE PERSON: 0001509160			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
	(a) [] (b) []					
3.	SEC USE ONLY	,				
4.	SOURCE OF FUNI	OS				
	00					
5.	CHECK BOX IF D	ISCLOSURE	OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(o	d) OR 2(e) []		
6.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	NUMBER OF	7.	SOLE VOTING POWER	0		
	SHARES					
	BENEFICIALLY OWNED BY	8.	SHARED VOTING POWER	3,443,455 (1)		
	EACH	9.	SOLE DISPOSITIVE POWER	0		
	REPORTING					
	PERSON WITH	10.	SHARED DISPOSITIVE POWER	3,443,455 (1)		
11.	AGGREGATE AM 3,443,455 (1)	OUNT BENE	FICIALLY OWNED BY EACH REPORTING PERSON			
12.	CHECK BOX IF TI	HE AGGREG	ATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			
13.	PERCENT OF CLA	SS REPRES	ENTED BY AMOUNT IN ROW (11)	19.65% (2)		
14.	TYPE OF REPORT					

 $^{(1) \ \} Includes \ 3,032,414 \ shares \ of \ common \ stock \ and \ warrants \ exercisable \ for \ an \ additional \ 411,041 \ shares.$

⁽²⁾ Based upon 17,117,152 shares of common stock outstanding as of October 24, 2013, as reported in the Issuer's prospectus supplement, dated October 25, 2013, filed pursuant to Rule 424(b)(5) on October 28, 2013.

CUSIP No. 572322402

1.	NAME OF REPOR	TING PERSO	ON .			
	Vivo Ventures VII Affiliates Fund, L.P.					
	I.R.S. IDENTIFICA	ATION NO. O	F ABOVE PERSON: 0001538309			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP					
	(a) [] (b) []				
3.	SEC USE ONLY					
4.	SOURCE OF FUNDS					
	00					
5.	CHECK BOX IF D	ISCLOSURE	OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	NUMBER OF	7.	SOLE VOTING POWER	0		
	SHARES					
	BENEFICIALLY	8.	SHARED VOTING POWER	75,048 (1)		
	OWNED BY					
	EACH	9.	SOLE DISPOSITIVE POWER	C		
	REPORTING		CVA DED DAGDOSTEVE DOLUMB	0 (0 (1)		
	PERSON WITH	10.	SHARED DISPOSITIVE POWER	75,048 (1)		
11.	AGGREGATE AM	OUNT BENE	FICIALLY OWNED BY EACH REPORTING PERSON			
	75,048 (1)					
12.	CHECK BOX IF T	HE AGGREC	ATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			
	[]		、 ,			
13.	PERCENT OF CLA	ASS REPRES	ENTED BY AMOUNT IN ROW (11)	0.44% (2)		
14.	TYPE OF REPORT	TING PERSO	N			
	PN					

 $^{(1) \ \} Includes \ 66,089 \ shares \ of \ common \ stock \ and \ warrants \ exercisable \ for \ an \ additional \ 8,959 \ shares.$

⁽²⁾ Based upon 17,117,152 shares of common stock outstanding as of October 24, 2013, as reported in the Issuer's prospectus supplement, dated October 25, 2013, filed pursuant to Rule 424(b)(5) on October 28, 2013.

CUSIP No. 572322402

1.	NAME OF REPOR	TING PERSO	DN.			
	Vivo Ventures V, LLC					
	I.R.S. IDENTIFICA	TION NO. O	F ABOVE PERSON: 84-1663511			
2.	CHECK THE APPR	ROPRIATE B	OX IF A MEMBER OF A GROUP			
	(a) [] (b) []					
3.	SEC USE ONLY					
4.	SOURCE OF FUNDS					
	00					
5.	CHECK BOX IF D	ISCLOSURE	OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	NUMBER OF	7.	SOLE VOTING POWER	0		
	SHARES					
	BENEFICIALLY	8.	SHARED VOTING POWER	204,416 (1)		
	OWNED BY					
	EACH	9.	SOLE DISPOSITIVE POWER	0		
	REPORTING					
	PERSON WITH	10.	SHARED DISPOSITIVE POWER	204,416 (1)		
11.	AGGREGATE AM	OUNT BENE	FICIALLY OWNED BY EACH REPORTING PERSON			
	204,416 (1)					
12.		HE AGGREG	ATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			
	[]		, , , , , , , , , , , , , , , , , , , ,			
13.	PERCENT OF CLA	ASS REPRES	ENTED BY AMOUNT IN ROW (11)	1.19% (2)		
14.	TYPE OF REPORT	ING PERSO	V			
	00					

- (1) Includes 178,169 shares of common stock and warrants exercisable for an additional 24,151 shares held of record by Vivo Ventures Fund V, L.P., and 1,846 shares of common stock and warrants exercisable for an additional 250 shares held of record by Vivo Ventures V Affiliates Fund, L.P. Vivo Ventures V, LLC is the sole general partner of both of the Vivo V Funds and may be deemed to beneficially own such shares, and disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.
- (2) Based upon 17,117,152 shares of common stock outstanding as of October 24, 2013, as reported in the Issuer's prospectus supplement, dated October 25, 2013, filed pursuant to Rule 424(b)(5) on October 28, 2013.

1.	NAME OF REPOR	TING PERSC	DN.			
	Vivo Ventures Fund V, L.P.					
	I.R.S. IDENTIFICA	TION NO. O	F ABOVE PERSON: 20-2588981			
2.			OX IF A MEMBER OF A GROUP			
(a) [] (b) []						
3.	SEC USE ONLY					
4.	SOURCE OF FUNDS					
	00					
5.	CHECK BOX IF DI	ISCLOSURE	OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []			
6.	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Delaware					
	NUMBER OF SHARES	7.	SOLE VOTING POWER	0		
	BENEFICIALLY OWNED BY	8.	SHARED VOTING POWER	202,320 (1)		
	EACH REPORTING	9.	SOLE DISPOSITIVE POWER	0		
	PERSON WITH	10.	SHARED DISPOSITIVE POWER	202,320 (1)		
11.	AGGREGATE AM0 202,320 (1)	OUNT BENE	FICIALLY OWNED BY EACH REPORTING PERSON			
12.	CHECK BOX IF TH	HE AGGREG	ATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			
13.	PERCENT OF CLA	SS REPRES	ENTED BY AMOUNT IN ROW (11)	1.18% (2)		
14.	TYPE OF REPORT PN					

⁽¹⁾ Includes 178,169 shares of common stock and warrants exercisable for an additional 24,151 shares.

⁽²⁾ Based upon 17,117,152 shares of common stock outstanding as of October 24, 2013, as reported in the Issuer's prospectus supplement, dated October 25, 2013, filed pursuant to Rule 424(b)(5) on October 28, 2013.

1.	NAME OF REPORTING PERSON. Vivo Ventures V Affiliates Fund, L.P.				
	I.R.S. IDENTIFICA	TION NO. C	F ABOVE PERSON: 20-3226166		
2.	CHECK THE APPE	ROPRIATE B	OX IF A MEMBER OF A GROUP		
	(a) [] (b) []			
3.	SEC USE ONLY	<u>/ []</u>			
1	SOURCE OF FUNI	os.			
••	00				
5.		ISCLOSURE	OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) []		
J.	CHECK BOX II B	BCLOSCIC	of Ebolic Procedubilities in responses Followith To Temio 2(a) on 2(c)		
6.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
	NUMBER OF	7.	SOLE VOTING POWER	0	
	SHARES				
	BENEFICIALLY	8.	SHARED VOTING POWER	2,096 (1)	
	OWNED BY				
	EACH	9.	SOLE DISPOSITIVE POWER	0	
	REPORTING				
	PERSON	10.	SHARED DISPOSITIVE POWER	2,096 (1)	
		10.	SHARED DISPOSITIVE POWER	2,096 (1)	
11.	PERSON WITH	101	SHARED DISPOSITIVE POWER EFICIALLY OWNED BY EACH REPORTING PERSON	2,096 (1)	
11.	PERSON WITH	101		2,096 (1)	
11. 12.	PERSON WITH AGGREGATE AM 2,096 (1)	OUNT BENE		2,096 (1)	
	PERSON WITH AGGREGATE AM 2,096 (1)	OUNT BENE	EFICIALLY OWNED BY EACH REPORTING PERSON	2,096 (1)	
	PERSON WITH AGGREGATE AM 2,096 (1) CHECK BOX IF TI	OUNT BENE	EFICIALLY OWNED BY EACH REPORTING PERSON	2,096 (1) 0.01% (2)	
12.	PERSON WITH AGGREGATE AM 2,096 (1) CHECK BOX IF TI	OUNT BENE	EFICIALLY OWNED BY EACH REPORTING PERSON GATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ENTED BY AMOUNT IN ROW (11)		

⁽¹⁾ Includes 1,846 shares of common stock and warrants exercisable for an additional 250 shares.

⁽²⁾ Based upon 17,117,152 shares of common stock outstanding as of October 24, 2013, as reported in the Issuer's prospectus supplement, dated October 25, 2013, filed pursuant to Rule 424(b)(5) on October 28, 2013.

SCHEDULE 13D

Explanatory Note: This Amendment No. 2 (the "Amendment") amends and supplements the statement on Schedule 13D filed on December 21, 2012, as amended on June 14, 2013, (the "Prior 13D") by the Reporting Persons relates to the common stock, par value \$0.00000002 per share (the "Common Stock") of MEI Pharma, Inc., a Delaware corporation (the "Issuer"). The address of the principal executive offices of the Issuer is 11975 El Camino Real, Suite 101, San Diego, CA 92130.

Except as specifically provided herein, this Amendment does not modify any of the information previously reported on the Prior 13D. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Prior 13D.

Item 4. Purpose of Transaction

Item 4 of the Statement is hereby amended to add the following:

The Reporting Persons sold 7,763 shares of Common Stock on June 28, 2013, 101,090 shares of Common Stock on October 1, 2013, 514,350 shares of Common Stock on October 2, 2013, 275,000 shares of Common Stock on October 25, 2013, 41,216 shares of Common Stock on October 28, 2013 and 800 shares of Common Stock on October 29, 2013.

Item 5. Interest in Securities of Issuer

This Amendment amends and restates Item 5 of the Prior 13D in its entirety as set forth below:

- (a) The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Schedule 13D.
- (b) The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Schedule 13D.
- (c) Except as disclosed in Item 4, none of the Reporting Persons or their affiliates has effected any other transactions in the securities of the Issuer during the past 60 days.
- (d) Not Applicable.
- (e) Not Applicable.

Item 7. Materials to be Filed as Exhibits

99.1 Joint Filing Agreement

Signature

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATED: October 30, 2013

Vivo Ventures VII, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund VII, L.P.

By: Vivo Ventures VII, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha

Title: Managing Member

Vivo Ventures VII Affiliates Fund, L.P.

By: Vivo Ventures VII, LLC, its General Partner

By: /s/ Albert Cha

Name: Albert Cha

Vivo Ventures V, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund V, L.P.

By: Vivo Ventures V, LLC, its General

Partner

By: /s/ Albert Cha

Name: Albert Cha

Title: Managing Member

Vivo Ventures V Affiliates Fund, L.P.

By: Vivo Ventures V, LLC, its General

Partner

By: /s/ Albert Cha

Name: Albert Cha

JOINT FILING AGREEMENT

In accordance with Rule 16a-3(j) and Rule 13d-1(k)(1) and under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of Schedules 13D and 13G (including any and all amendments thereto) with respect to the Common Stock, par value \$0.00000002 per share, of MEI Pharma, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Forms Schedules 13D and l3G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; <u>provided</u> that no party is responsible for the completeness or accuracy of the information concerning any other filing party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.

In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of October 30, 2013.

Vivo Ventures VII, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund VII, L.P.

By: Vivo Ventures VII, LLC, its General

Partner

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures VII Affiliates Fund, L.P.

By: Vivo Ventures VII, LLC, its General

Partner

By: /s/ Albert Cha

Name: Albert Cha

Vivo Ventures V, LLC

By: /s/ Albert Cha

Name: Albert Cha Title: Managing Member

Vivo Ventures Fund V, L.P.

By: Vivo Ventures V, LLC, its General

Partner

By: /s/ Albert Cha

Name: Albert Cha

Title: Managing Member

Vivo Ventures V Affiliates Fund, L.P.

By: Vivo Ventures V, LLC, its General

Partner

By: /s/ Albert Cha

Name: Albert Cha